| Nome |
# |
|
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial, file dd9e0c6a-5939-1e9c-e053-3a05fe0a45ef
|
1.377
|
|
Vitamin K effects in human health: new insights beyond bone and cardiovascular health, file dd9e0c6a-b9dc-1e9c-e053-3a05fe0a45ef
|
421
|
|
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma, file dd9e0c6a-883e-1e9c-e053-3a05fe0a45ef
|
233
|
|
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?, file dd9e0c6a-d6ff-1e9c-e053-3a05fe0a45ef
|
192
|
|
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, file dd9e0c6a-9ce8-1e9c-e053-3a05fe0a45ef
|
168
|
|
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium, file dd9e0c6a-d8cc-1e9c-e053-3a05fe0a45ef
|
156
|
|
Transplantation of kidneys with tumors, file dd9e0c6a-9dcc-1e9c-e053-3a05fe0a45ef
|
151
|
|
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, file dd9e0c6b-153f-1e9c-e053-3a05fe0a45ef
|
118
|
|
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma, file dd9e0c6a-6c6c-1e9c-e053-3a05fe0a45ef
|
116
|
|
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials, file dd9e0c6a-bf89-1e9c-e053-3a05fe0a45ef
|
112
|
|
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study, file dd9e0c6a-5b05-1e9c-e053-3a05fe0a45ef
|
106
|
|
The adjuvant treatment of kidney cancer: a multidisciplinary outlook, file dd9e0c6a-6ab2-1e9c-e053-3a05fe0a45ef
|
99
|
|
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis, file dd9e0c6a-c316-1e9c-e053-3a05fe0a45ef
|
93
|
|
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper, file dd9e0c66-12b1-1e9c-e053-3a05fe0a45ef
|
72
|
|
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma, file dd9e0c6a-c2a0-1e9c-e053-3a05fe0a45ef
|
71
|
|
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale, file dd9e0c6a-cede-1e9c-e053-3a05fe0a45ef
|
68
|
|
Opening an onconephrology clinic: Recommendations and basic requirements, file dd9e0c6a-639e-1e9c-e053-3a05fe0a45ef
|
61
|
|
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison, file dd9e0c6a-a7d2-1e9c-e053-3a05fe0a45ef
|
59
|
|
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells, file dd9e0c6a-6393-1e9c-e053-3a05fe0a45ef
|
57
|
|
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme, file dd9e0c6a-78db-1e9c-e053-3a05fe0a45ef
|
56
|
|
Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma, file dd9e0c6a-c627-1e9c-e053-3a05fe0a45ef
|
56
|
|
Sunitinib in the treatment of renal cell carcinoma: An update on recent evidence, file dd9e0c6a-9dd1-1e9c-e053-3a05fe0a45ef
|
52
|
|
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium, file dd9e0c6a-c464-1e9c-e053-3a05fe0a45ef
|
51
|
|
Management of poor-risk metastatic renal cell carcinoma: Current approaches, the role of temsirolimus and future directions, file dd9e0c6a-9dce-1e9c-e053-3a05fe0a45ef
|
49
|
|
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance, file dd9e0c6b-08c8-1e9c-e053-3a05fe0a45ef
|
48
|
|
Pazopanib in patients with clear-cell renal cell carcinoma: Seeking the right patient, file dd9e0c6a-c462-1e9c-e053-3a05fe0a45ef
|
47
|
|
Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy, file dd9e0c6a-f7de-1e9c-e053-3a05fe0a45ef
|
47
|
|
The role of the cell-cell interactions in cancer progression, file dd9e0c6a-c314-1e9c-e053-3a05fe0a45ef
|
45
|
|
Prognostic Value of 18 F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel, file dd9e0c6a-d702-1e9c-e053-3a05fe0a45ef
|
45
|
|
Insulin-like growth factor-1 signaling in renal cell carcinoma, file dd9e0c6a-dd29-1e9c-e053-3a05fe0a45ef
|
45
|
|
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)], file dd9e0c6b-2471-1e9c-e053-3a05fe0a45ef
|
45
|
|
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma, file dd9e0c6a-6c71-1e9c-e053-3a05fe0a45ef
|
43
|
|
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker?, file dd9e0c6a-a990-1e9c-e053-3a05fe0a45ef
|
43
|
|
Comparing comparators: A look at control arms in kidney cancer studies over the years, file dd9e0c6a-da94-1e9c-e053-3a05fe0a45ef
|
43
|
|
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma, file dd9e0c6a-592f-1e9c-e053-3a05fe0a45ef
|
42
|
|
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma, file dd9e0c6a-5dc0-1e9c-e053-3a05fe0a45ef
|
42
|
|
Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model, file dd9e0c6a-8e5e-1e9c-e053-3a05fe0a45ef
|
42
|
|
Choosing the right cell line for renal cell cancer research, file dd9e0c6a-bf82-1e9c-e053-3a05fe0a45ef
|
42
|
|
Renin angiotensin system deregulation as renal cancer risk factor (Review), file dd9e0c6a-d7e4-1e9c-e053-3a05fe0a45ef
|
42
|
|
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials, file dd9e0c6a-f1d4-1e9c-e053-3a05fe0a45ef
|
42
|
|
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma, file dd9e0c6a-f69a-1e9c-e053-3a05fe0a45ef
|
42
|
|
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program, file dd9e0c6b-2909-1e9c-e053-3a05fe0a45ef
|
42
|
|
ASSURE vs. S-TRAC: Conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics, file dd9e0c6b-2dca-1e9c-e053-3a05fe0a45ef
|
42
|
|
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma, file dd9e0c6a-eaee-1e9c-e053-3a05fe0a45ef
|
41
|
|
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas, file dd9e0c6a-f69d-1e9c-e053-3a05fe0a45ef
|
41
|
|
Glomerular diseases and cancer: evaluation of underlying malignancy, file dd9e0c6a-6738-1e9c-e053-3a05fe0a45ef
|
40
|
|
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma, file dd9e0c6a-c4bd-1e9c-e053-3a05fe0a45ef
|
40
|
|
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes, file dd9e0c6a-d557-1e9c-e053-3a05fe0a45ef
|
39
|
|
Hormone signaling pathways as treatment targets in renal cell cancer (Review), file dd9e0c6a-d709-1e9c-e053-3a05fe0a45ef
|
39
|
|
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib, file dd9e0c6a-e92e-1e9c-e053-3a05fe0a45ef
|
39
|
|
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma, file dd9e0c6b-11c5-1e9c-e053-3a05fe0a45ef
|
39
|
|
Onco-nephrology: A decalogue, file dd9e0c6a-97a9-1e9c-e053-3a05fe0a45ef
|
38
|
|
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project, file dd9e0c6a-c0d9-1e9c-e053-3a05fe0a45ef
|
38
|
|
Clinical impact of Pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis, file dd9e0c6a-f1cf-1e9c-e053-3a05fe0a45ef
|
38
|
|
Wide spetcrum mutational analysis of metastatic renal cell cancer: A retrospective next generation sequencing approach, file dd9e0c6b-2dc8-1e9c-e053-3a05fe0a45ef
|
38
|
|
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis?, file d42878ed-303c-410f-aae5-2a8a38c7219f
|
11
|
|
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib, file dd9e0c6b-eb7b-1e9c-e053-3a05fe0a45ef
|
6
|
|
Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines, file dd9e0c6a-6b7a-1e9c-e053-3a05fe0a45ef
|
5
|
|
Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA, file dd9e0c6b-2c77-1e9c-e053-3a05fe0a45ef
|
5
|
|
Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research, file dd9e0c6b-a7f8-1e9c-e053-3a05fe0a45ef
|
3
|
|
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study), file dd9e0c6b-d9e7-1e9c-e053-3a05fe0a45ef
|
3
|
|
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review, file dd9e0c6c-71ab-1e9c-e053-3a05fe0a45ef
|
3
|
|
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?, file 9aa6c359-4876-4399-b916-bdc28e948710
|
2
|
|
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies, file dd9e0c66-de85-1e9c-e053-3a05fe0a45ef
|
2
|
|
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?, file dd9e0c6a-bd7a-1e9c-e053-3a05fe0a45ef
|
2
|
|
Toward a genome-based treatment landscape for renal cell carcinoma, file dd9e0c6b-2c14-1e9c-e053-3a05fe0a45ef
|
2
|
|
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?, file dd9e0c6b-b6bd-1e9c-e053-3a05fe0a45ef
|
2
|
|
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study), file dd9e0c6b-d382-1e9c-e053-3a05fe0a45ef
|
2
|
|
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system, file dd9e0c6b-d457-1e9c-e053-3a05fe0a45ef
|
2
|
|
Beyond ras and braf: Her2, a new actionable oncotarget in advanced colorectal cancer, file dd9e0c6b-d96f-1e9c-e053-3a05fe0a45ef
|
2
|
|
Biological therapeutic advances for the treatment of advanced urothelial cancers, file dd9e0c6b-fd79-1e9c-e053-3a05fe0a45ef
|
2
|
|
Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma, file dd9e0c6c-0b6c-1e9c-e053-3a05fe0a45ef
|
2
|
|
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak, file dd9e0c6c-0b72-1e9c-e053-3a05fe0a45ef
|
2
|
|
Playing the devil’s advocate: Should we give a second chance to mTOR inhibition in renal clear cell carcinoma? – ie strategies to revert resistance to mtor inhibitors, file dd9e0c6c-0b76-1e9c-e053-3a05fe0a45ef
|
2
|
|
Second-line treatment in renal cell carcinoma: clinical experience and decision making, file dd9e0c6c-0eed-1e9c-e053-3a05fe0a45ef
|
2
|
|
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer, file dd9e0c6c-2d28-1e9c-e053-3a05fe0a45ef
|
2
|
|
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma, file dd9e0c6c-4ed9-1e9c-e053-3a05fe0a45ef
|
2
|
|
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts, file dd9e0c6c-4eda-1e9c-e053-3a05fe0a45ef
|
2
|
|
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations, file 416890f3-ecfb-4c82-a6b9-1f9a7c2809f4
|
1
|
|
Hepatocellular carcinoma, vascular endothelial growth factor receptors‐targeting agents, and hypertension: A much more complicated relationship than expected, file 5c456be3-90ac-4ff6-9d1a-679cdacd5c5a
|
1
|
|
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art, file dd9e0c69-815a-1e9c-e053-3a05fe0a45ef
|
1
|
|
Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents, file dd9e0c6a-63a2-1e9c-e053-3a05fe0a45ef
|
1
|
|
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program, file dd9e0c6a-656a-1e9c-e053-3a05fe0a45ef
|
1
|
|
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214, file dd9e0c6a-680e-1e9c-e053-3a05fe0a45ef
|
1
|
|
Targeting angiogenesis in metastatic renal cell carcinoma, file dd9e0c6a-6aad-1e9c-e053-3a05fe0a45ef
|
1
|
|
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review, file dd9e0c6a-6b7d-1e9c-e053-3a05fe0a45ef
|
1
|
|
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?, file dd9e0c6a-6e26-1e9c-e053-3a05fe0a45ef
|
1
|
|
Acute Kidney Injury in Cancer Patients, file dd9e0c6a-6fe5-1e9c-e053-3a05fe0a45ef
|
1
|
|
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium, file dd9e0c6a-7138-1e9c-e053-3a05fe0a45ef
|
1
|
|
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial, file dd9e0c6a-7c51-1e9c-e053-3a05fe0a45ef
|
1
|
|
The effect of a treatment delay on outcome in metastatic renal cell carcinoma, file dd9e0c6a-7c5a-1e9c-e053-3a05fe0a45ef
|
1
|
|
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials, file dd9e0c6a-812f-1e9c-e053-3a05fe0a45ef
|
1
|
|
Pharmacotherapy for treating metastatic clear cell renal cell carcinoma, file dd9e0c6a-8282-1e9c-e053-3a05fe0a45ef
|
1
|
|
Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities, file dd9e0c6a-8447-1e9c-e053-3a05fe0a45ef
|
1
|
|
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer, file dd9e0c6a-8ad9-1e9c-e053-3a05fe0a45ef
|
1
|
|
Telomeric repeat-CONTAINING RNAs (TERRA) decrease in squamous cell carcinoma of the head and neck is associated withWorsened clinical outcome, file dd9e0c6a-8e59-1e9c-e053-3a05fe0a45ef
|
1
|
|
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma, file dd9e0c6a-8e60-1e9c-e053-3a05fe0a45ef
|
1
|
|
Renal cell carcinoma treatment after first-line combinations, file dd9e0c6a-9ced-1e9c-e053-3a05fe0a45ef
|
1
|
|
Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient, file dd9e0c6a-9cf0-1e9c-e053-3a05fe0a45ef
|
1
|
|
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium, file dd9e0c6a-9cf3-1e9c-e053-3a05fe0a45ef
|
1
|
| Totale |
5.383 |